

Investor Contact:

Robert G. Burrows
Vice President, Investor Relations
240-631-3280
BurrowsR@ebsi.com

Media Contact:

Tracey Schmitt Lintott
Senior Vice President, Global Public Affairs
240-631-3394
SchmittT@ebsi.com

EMERGENT BIOSOLUTIONS TO PARTICIPATE IN FIRST QUARTER 2017 INVESTOR CONFERENCES

GAITHERSBURG, MD, December 29, 2016— Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company's senior management team will participate in the following investor conferences during the first quarter of 2017.

- **35th Annual J.P. Morgan Healthcare Conference**
San Francisco, CA
January 9-12, 2017
Presentation: January 10, 2017
- **Wells Fargo Specialty and Generic Drug Summit**
Orlando, FL
February 13, 2017
Presentation time TBD
- **Cowen & Co. 37th Annual Health Care Conference**
Boston, MA
March 6-8, 2017
Presentation day and time TBD

Presentation dates and times will be updated on the Emergent website www.emergentbiosolutions.com under "Investors" as this information becomes available.

For these conferences, the company will be webcasting its presentation, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance. The webcasts will be available both live and by replay, accessible from the Emergent website.

About Emergent BioSolutions

Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us @emergentbiosolu.

###